Search results

Integrin receptor found on platelets for fibrinogen, and aids in platelet activation.

Auto-populated based on [[Special:WhatLinksHere/Platelet glycoprotein GPIIb-IIIa complex]]. Needs checking by a human. {{r|Platelet aggregation inhibitors}}

{{r|Platelet aggregation inhibitors}} {{r|Platelet}}

{{r|Platelet glycoprotein GPIIb-IIIa complex}} {{r|Platelet}}

...)|plasma]]; the primary types being [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s

Auto-populated based on [[Special:WhatLinksHere/Platelet]]. Needs checking by a human. {{r|Platelet activation}}

...[[Adenosine diphosphate|ADP]] or [[Adenosine triphosphate|ATP]] mediates [[platelet]] aggregation.

'''Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit''' (or PAFAH1B

...d components (or whole blood) such as [[erythrocyte]]s, [[leukocyte]]s, [[platelet]]s, and plasma from a donor to a recipient or back to the donor. Blood comp * [[Platelet transfusion]]

...atelet]]s by fragmenting into small, odd-shaped pieces. These fragments ([[platelet]]s) of the megakaryocyte's [[cytoplasm]] circulate in the blood as the body ...its contents all at once in the marrow. Alternatively, the cell may form platelet ribbons into blood vessels. The ribbons are formed via psuedopodia and the

{{r|Platelet}}

{{r|Platelet}}

{{r|Platelet activation}}

In [[pharmacology]], '''prasugrel''' is a [[platelet aggregation inhibitor]] of the [[thienopyridine]] class that blocks [[adeno

{{r|Platelet}}

...' include [[eptifibatide]] and [[tirofiban]]. These medication block the [[platelet glycoprotein GPIIb-IIIa complex]] and are used for treating [[acute coronar

{{r|Platelet||**}}

...d concentration, reduces incidence of cardiovascular disorders, prevents [[platelet aggregation]], and inhibits [[arachidonic acid]] conversion into the [[thro

{{r|Platelet glycoprotein GPIIb-IIIa complex}}

{{r|Platelet}}

...nal |author=Fritz E, Ludwig H, Scheithauer W, Sinzinger H |title=Shortened platelet half-life in multiple myeloma |journal=Blood |volume=68 |issue=2 |pages=514 ...s Disease. The chronic form in adults is usually caused by antibodies to [[Platelet glycoprotein GPIIb-IIIa complex]] or Ib-IX.<ref name="isbn0-7216-0187-1"/>

.../> This leaves vasoconstriction, platelet aggregation, and thrombosis from platelet thromboxane A2 mediated by COX-1 intact.<ref name="pmid-16968830"/>

{{r|Platelet}}

{{r|Platelet}}

{{r|Platelet}}

{{r|Platelet}}

{{r|Platelet}}

...actor complex. The von Willebrand factor has receptors for [[collagen]], [[platelet]]s, and [[ristocetin]] activity as well as the immunologically distinct ant

{{r|Platelet}}

{{r|Platelet}}

...'''cangrelor''' is an [[purinergic P2Y receptor antagonist]]s that is a [[platelet aggregation inhibitor]]. ...Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al.| title=Effect of platelet inhibition with cangrelor during PCI on ischemic events. | journal=N Engl J

{{r|Platelet}}

{{r|Platelet transfusion}}

...antagonize or impair any mechanism leading to blood [[platelet activation|platelet aggregation]], whether during the phases of activation and shape change or Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]

{{r|Platelet}}

{{r|Platelet}}

==Anatomy of a platelet== ...brand factor]]), the contents of which are released upon activation of the platelet. These granule contents play an important role in both [[hemostasis]] and i

...nce of [[fibrin]] strands following the mixing of plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of t

...nism of [[phagocytosis]]. They produce [[leukotriene]] C₄ and [[platelet activation factor]] (PAF). <ref name=Ganong>{{citation ...Ganong, p. 508</ref> Especially infectious parasites produce inhibitors of platelet aggregation.<ref name=Liu>{{citation

...of [[hematoepoesis]]: generation of [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s from [[hematopoetic stem cell]]s.

{{r|Platelet||**}}

{{r|Platelet-derived growth factor receptor||**}}

...nthase]] by acetylating its terminal amino group. Aspirin also inhibits [[platelet]] aggregation and is used in the prevention of arterial and venous [[thromb Individuals in whom platelet function assays demonstrate resistance to aspirin are less likely to have c

...s]] include [[leukocyte]]s for immune and infection-fighting action, and [[platelet]]s for clotting.

...eptor]]s, and [[purinoceptor P2Y12|purinoceptor P2Y₁₂]] (causes platelet aggregation).

*[[Platelet]]s per unit volume

...ansduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway."<ref>{{MeSH}}</ref>

...('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. C

...hich leads to profound low [[white blood cell]], [[red blood cell]], and [[platelet]] counts.

...does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]].